Pacira BioSciences, Inc.PCRXNASDAQ
Loading
Year-over-year net income growth rate
Percentile
P41
Within normal range
vs 2Y Ago
-0.5x
Contraction
Streak
1 qtr
Consecutive declineDecelerating
| Period | Value |
|---|---|
| Q4 2025 | -69.86% |
| Q3 2025 | 212.07% |
| Q2 2025 | -200.73% |
| Q1 2025 | -70.00% |
| Q4 2024 | 111.18% |
| Q3 2024 | -859.64% |
| Q2 2024 | 110.34% |
| Q1 2024 | -63.90% |
| Q4 2023 | 129.05% |
| Q3 2023 | -57.85% |
| Q2 2023 | 231.87% |
| Q1 2023 | -93.39% |
| Q4 2022 | -1357.72% |
| Q3 2022 | -103.49% |
| Q2 2022 | 191.10% |
| Q1 2022 | 233.10% |
| Q4 2021 | -129.05% |
| Q3 2021 | -7.45% |
| Q2 2021 | 84.02% |
| Q1 2021 | -28.56% |
| Q4 2020 | -88.84% |
| Q3 2020 | 1890.05% |
| Q2 2020 | -189.09% |
| Q1 2020 | 266.92% |
| Q4 2019 | 19.70% |
| Q3 2019 | -322.97% |
| Q2 2019 | 198.52% |
| Q1 2019 | -133.45% |
| Q4 2018 | 1394.53% |
| Q3 2018 | -124.96% |
| Q2 2018 | 124.01% |
| Q1 2018 | -332.43% |
| Q4 2017 | 160.48% |
| Q3 2017 | 61.52% |
| Q2 2017 | 0.62% |
| Q1 2017 | -400.03% |
| Q4 2016 | 82.07% |
| Q3 2016 | -178.51% |
| Q2 2016 | -106.49% |
| Q1 2016 | -54.28% |